Haiyong Han

Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.

Targeting Aurora-2 kinase in cancer.

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.

Laminin-5 beta3A expression in LNCaP human prostate carcinoma cells increases cell migration and tumorigenicity.

Hitting multiple targets with multimeric ligands.

PRL phosphatases as potential molecular targets in cancer.

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.

Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.

Aurora sheds light on head and neck squamous cell carcinoma.

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.

Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.

Identification of a novel inhibitor of urokinase-type plasminogen activator.

Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.

Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.

Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer.

Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification.

UA62784, a novel inhibitor of centromere protein E kinesin-like protein.

Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells.

Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer.

Enhanced targeting with heterobivalent ligands.

Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.

Identification of pancreatic cancer-specific cell-surface markers for development of targeting ligands.

Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray.

Cell cycle arrest and apoptosis induction by an anticancer chalcone epoxide.

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

Perineural invasion and associated pain in pancreatic cancer.

Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells.

Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look.

Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.

Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.

Molecular Characterization of a Patient's Small Cell Carcinoma of the Ovary of the Hypercalcemic Type.

Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells.

Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling.

Characterization of a membrane-active anti-tumor agent, UA8967.

Tumor-stromal interactions in pancreatic cancer.

SnapShot: pancreatic cancer.

Isolation and characterization of muscle fatigue substance with anti-tumor activities.

Discrimination between Adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis.

Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.

Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction.

Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review.

Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells.

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma.